RCUSPhase 3 Readout
STAR-221 interim analysis window
Arcus Biosciences | Domvanalimab | Upper GI cancers
Catalyst details
Phase 3 TIGIT plus PD-1 combination readout tracked from company disclosures.
Phase
Phase 3
Expected date
2026-08-15
Expected period
Q3 2026
Source type
manual
quarterupcoming
Source URLNotes
This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.
Open company detailHistory of changes
No sample changes for this catalyst.